Cao Wei, Xiao Xianjun, Zhang Leixiao, Liu Ying, Wang Lu, Zou Zihao, Cao Yue, Li Chunxiao, Zheng Qianhua, Zhou Siyuan, Li Ying
Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine.
Rehabilitation Department, The People's Hospital of Jianyang City.
Medicine (Baltimore). 2020 Aug 14;99(33):e21624. doi: 10.1097/MD.0000000000021624.
To investigate the efficacy and safety of compound glycyrrhizin (CG) combined with antihistamines in the treatment of chronic urticaria (CU).
We will use computers to search all databases including Medline, Embase, Pubmed, Web of Science and Cochrane Central Register of Controlled Trials and China's 4 databases: China National Knowledge Infrastructure Database, China Biomedical Literature Database, China Science Journal Database, and Wanfang Database. Find data from creation date to July 2020. In addition, we will manually search the list of medical journals as a supplement. The scope of the search included randomized controlled clinical studies related to CG combined with antihistamines for CU. The primary outcome is the disease activity control. Secondary outcomes include response rate, adverse events, and recurrence rates. The Cochrane RevMan V5.3 Deviation Assessment Tool will be used to assess bias assessment risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). The average difference, standard mean difference, and binary data will be used to represent continuous results.
This study will comprehensively review the existing evidence on CG combined with antihistamines for CU.
This systematic review will provide a basis for judging the effectiveness and safety of CG combined with antihistamines in the treatment of CU.
PROSPERO, CRD42020156153.
探讨复方甘草酸苷(CG)联合抗组胺药治疗慢性荨麻疹(CU)的疗效和安全性。
我们将使用计算机检索所有数据库,包括Medline、Embase、Pubmed、Web of Science和Cochrane对照试验中央注册库以及中国的4个数据库:中国知网数据库、中国生物医学文献数据库、中国科学期刊数据库和万方数据库。查找从创建日期到2020年7月的数据。此外,我们将手动检索医学期刊列表作为补充。检索范围包括与CG联合抗组胺药治疗CU相关的随机对照临床研究。主要结局是疾病活动控制。次要结局包括有效率、不良事件和复发率。将使用Cochrane RevMan V5.3偏差评估工具评估偏倚评估风险、数据整合风险、荟萃分析风险和亚组分析风险(如果条件满足)。平均差、标准化均数差和二分类数据将用于表示连续结果。
本研究将全面综述CG联合抗组胺药治疗CU的现有证据。
本系统评价将为判断CG联合抗组胺药治疗CU的有效性和安全性提供依据。
PROSPERO,CRD42020156153。